$911 Million is the total value of Consonance Capital Management LP's 23 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 43.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CLVS | Sell | CLOVIS ONCOLOGY INC | $121,306,000 | -4.7% | 2,730,887 | -22.7% | 13.32% | +8.7% |
| HZNP | Buy | HORIZON PHARMA PLC | $93,745,000 | +39.8% | 5,793,903 | +56.6% | 10.30% | +59.5% |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $83,290,000 | -13.8% | 580,701 | -29.1% | 9.15% | -1.7% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $77,161,000 | -1.9% | 25,052,380 | +1.6% | 8.47% | +12.0% |
| MNKKQ | Sell | MALLINCKRODT PUB LTD CO | $57,489,000 | -47.2% | 1,153,944 | -26.0% | 6.31% | -39.7% |
| RTRX | Sell | RETROPHIN INC | $52,477,000 | -24.0% | 2,772,156 | -10.1% | 5.76% | -13.3% |
| ATRC | Buy | ATRICURE INC | $52,181,000 | +1323.0% | 2,666,354 | +1049.7% | 5.73% | +1523.2% |
| GMED | GLOBUS MED INCcl a | $46,165,000 | +10.0% | 1,860,000 | 0.0% | 5.07% | +25.5% | |
| ARIA | Sell | ARIAD PHARMACEUTICALS INC | $44,211,000 | -62.9% | 3,553,943 | -59.1% | 4.86% | -57.6% |
| MD | MEDNAX INC | $43,996,000 | +0.6% | 660,000 | 0.0% | 4.83% | +14.8% | |
| MYGN | Buy | MYRIAD GENETICS INC | $38,823,000 | +122.0% | 2,328,932 | +174.0% | 4.26% | +153.4% |
| MACK | Buy | MERRIMACK PHARMACEUTICALS IN | $36,997,000 | -2.1% | 9,067,998 | +52.4% | 4.06% | +11.7% |
| AMAG | New | AMAG PHARMACEUTICALS INC | $35,736,000 | – | 1,026,902 | +100.0% | 3.92% | – |
| ANIP | Sell | ANI PHARMACEUTICALS INC | $29,801,000 | -31.2% | 491,608 | -24.7% | 3.27% | -21.5% |
| ARRY | New | ARRAY BIOPHARMA INC | $23,912,000 | – | 2,723,471 | +100.0% | 2.63% | – |
| PCRX | New | PACIRA PHARMACEUTICALS INC | $20,407,000 | – | 631,805 | +100.0% | 2.24% | – |
| NVDQ | New | NOVADAQ TECHNOLOGIES INC | $17,109,000 | – | 2,413,179 | +100.0% | 1.88% | – |
| ACHC | New | ACADIA HEALTHCARE COMPANY IN | $16,903,000 | – | 510,666 | +100.0% | 1.86% | – |
| VCEL | Buy | VERICEL CORP | $8,949,000 | +43.1% | 2,982,940 | +33.6% | 0.98% | +63.3% |
| ADMA | ADMA BIOLOGICS INC | $6,523,000 | -29.3% | 1,273,933 | 0.0% | 0.72% | -19.4% | |
| BIOL | Sell | BIOLASE INC | $2,029,000 | -35.3% | 1,449,022 | -19.1% | 0.22% | -26.2% |
| SPNE | Sell | SEASPINE HLDGS CORP | $1,012,000 | -61.9% | 128,127 | -51.3% | 0.11% | -56.6% |
| VCYT | Sell | VERACYTE INC | $362,000 | -71.3% | 46,752 | -71.8% | 0.04% | -66.9% |
| HSTM | Exit | HEALTHSTREAM INC | $0 | – | -340,847 | -100.0% | -0.90% | – |
| EHTH | Exit | EHEALTH INC | $0 | – | -1,154,711 | -100.0% | -1.25% | – |
| OFIX | Exit | ORTHOFIX INTL N V | $0 | – | -634,496 | -100.0% | -2.61% | – |
| IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -3,296,539 | -100.0% | -5.04% | – |
| AKRXQ | Exit | AKORN INC | $0 | – | -2,200,000 | -100.0% | -5.77% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.